StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock. Separately, HC Wainwright dropped their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a […]

Related Keywords

, Oncternal Therapeutics Company Profile , Securities Exchange Commission , Nasdaq , Oncternal Therapeutics Inc , Pasadena Private Wealth , Oncternal Therapeutics , Get Free Report , Director Robert James Wills , Exchange Commission , Private Wealth , Free Report , Orphan Receptor , Oncternal Therapeutics Daily ,